GROUP
2022 FOURTH QUARTER (oct-dec)
- Net sales of products 10 191 (5 642) tkr
- Gross profit 4 302 (3 388) tkr, 42% (60%)
- Adjusted gross profit 5 313 (3 388) tkr, 52% (60%)[i]
- Operating loss -6 890 (-43 974) tkr
- Loss per share -0,03 (-0,23) kr
FULL YEAR 2022 (jan-dec)
- Net sales of products 43 634 (31 643) tkr
- Gross profit 23 394 (19 070) tkr, 54% (60%)
- Operating loss -33 606 (-73 718) tkr
- Loss per share -0,15 (-0,38) kr
Before inventory adjustments that fully charge quarter 4 instead of being distributed over previous quarters.
From the CEO
Peptonic’s strategy shift in 2022 has set the company in a positive direction
Despite current society-wide challenges, Peptonic’s growth in 2022 showed a clearly positive trend. Q4 2022 was the third financial quarter in a row that had significant improvement compared to the one before it. The primary reason for the trend is a successful strategy shift that was made at the beginning of 2022 in connection with the incorporation of Israeli CommonSense, which was acquired at the end of 2021 and is now Peptonic Israel.
At the beginning of 2022, the company divided its business into two areas: Medical Consumer — featuring Intimate self-care products that are clinically proven and based on a concept of “diagnose, treat, prevent” — and LifeStyle Consumer — featuring solutions composed mainly of durable menstrual products. The separation created greater clarity, both internally and externally, which has improved focus, cost efficiency, and consumer reception. That, in turn, has improved company performance. The Medical Consumer business area currently accounts for approximately two-thirds of Peptonic’s turnover.
Strong reception to the “diagnose, treat, prevent” concept
Peptonic created a unifying concept within its Medical Consumer portfolio of products. The solutions are connected by the ability they offer consumers to diagnose, treat, and prevent vaginal health issues themselves. So far, the concept has been received with great interest. Peptonic’s vaginal self-tests were presented at the annual conference of Sweden’s national association of gynecologists, SFOG 2022, and given a very positive reception. In the spring of 2023, Peptonic will launch an educational project for Swedish gynecologists regarding the products’ usage and benefits. The response from pharmacies in Sweden has also been very positive, and all of the major chains now list Peptonic’s self-test for vaginal infections for digital purchase. The company expects the expansion of pharmacy distribution to continue in 2023. In 2022, Peptonic’s Medical Consumer products grew organically by more than 50% in its home market of Sweden.
Increasing interest from international partners
International demand for Peptonic’s products increased throughout 2022. This was, above all, mostly regarding the company’s vaginal self-tests. Existing partners such as Bayer, Exeltis, Walgreens, and CVS regularly ordered significant product volumes. New distributor agreements were signed with Windsor Pharma for Central America, German Medical Store for the United Arab Emirates, and InVivo Pharma for Georgia. The company expects more distributor agreements in 2023 and plans to add Peptonic’s gel treatment for vaginal dryness and preventive intimate cleanser to select distribution agreements for international markets where the vaginal self-tests are already sold.
Lunette’s contract agreement with the UN — an important signal of quality
In 2022, Peptonic’s LifeStyle Consumer business area also saw significant success for its Lunette brand. With Lunette, the company works hard to break stigmas and be an inclusive source of information and education about women’s health. As a result of those efforts, Lunette was awarded a long-term contract by the UN in 2022. Lunette was chosen as the supplier of menstrual cups for the UN’s hygiene kits. The first orders for the contract were placed at the end of 2022. This contract agreement not only has significant potential for future business but is a very public signal indicating the high quality of Peptonic’s Lunette brand.
Growing patent portfolio
An important part of Peptonic’s strategy is to develop innovations and protect them with patents. In 2022, Peptonic’s vaginal gel gained international approval for the treatment of vestibulitis. An adapted version of the gel also gained international approval for the treatment of vaginal fungal infections, which applies to the company’s moisturizing intimate cleanser as well.
Successful fundraising to create conditions for profitability
Peptonic has just closed the first part of an ongoing round of funding. It’s financing that, with a rights issue and the associated warrant series, should give the company the conditions to implement strategy and become profitable. In response to the rights issue, which ended in February 2023, the company raised SEK 55 million before issue costs of which amounted to approximately SEK 10 million, of which SEK 4.9 million referred to guarantee compensation. Given the current financial climate, this was a very successful result. The proceeds will be used to accelerate the development of the product portfolio, strengthen the organization, increase marketing, and repay loans. In connection with the rights issue, Maida Vale Capital became a new major shareholder alongside the Vidarstiftelsen foundation. Maida Vale’s commitment to Peptonic is long-term and brings added value to the company with extensive industry experience and global networks.
I, along with the entire organization, feel confident about the company’s future.
Erik Sundquist
CEO
| KEY FIGURES | ||||
| Peptonic Group | ||||
| 12 mon | 12 mon | 12 mon | ||
| jan-dec | jan-dec | jan-dec | ||
| 2022 | 2021 | 2020 | ||
| Sales goods, KSEK | 43 634 | 31 643 | 21 283 | |
| Gross profit sales goods, KSEK | 23 394 | 19 070 | 13 089 | |
| Gross margin, % | 54% | 60% | 61% | |
| Operating profit, KSEK | -33 606 | -73 718 | -31 053 | |
| Return on equity,% | Neg | Neg | Neg | |
| Equity ratio,% | 55 | 62 | 88 | |
| Earnings per share, SEK | -0.15 | -0.38 | -0.19 | |
| Liquidity per share, SEK | 0.01 | 0.05 | 0.24 | |
| Equity per share, SEK | 0.19 | 0.27 | 0.72 | |
| Share price per closing, SEK | 0.14 | 0.63 | 1.73 | |
| Share price/Equity per share, SEK | 0.72 | 2.30 | 2.39 | |
| Equity per share, SEK | 242 743 544 | 191 639 642 | 162 911 613 |
FINANCIAL INFORMATION
Group
Revenue – Sales of goods during the fourth quarter amounted to SEK 10,191 (5,642) thousand, a growth of 80,6%. Other operating income for the quarter was SEK 1,733 (610) thousand and mainly consists of exchange rate adjustments and covid support.
In the full year, sales of goods amounted to SEK 43,634 (31,643) thousand corresponding to a sales increase of 37.9%. Other operating income for the period was SEK 2,770 (622) thousand.
Costs – Costs for the fourth quarter amounted to SEK -18,814 (-50,226) thousand. Costs for the full year were SEK -80,010 (-105,983) thousand.
Costs of goods sold for the quarter amounted to SEK -5,890 (-2,254) thousand, which corresponds to a gross profit of SEK 4,302 (3,388) thousand and a gross margin of 42% (60%). The relatively low gross profit and margin for the quarter is mainly explained by inventory adjustments which fully charged quarter 4 instead of being distributed over previous quarters. If the cost had been distributed over previous quarters, the fourth quarter’s gross profit and gross margin would have amounted to SEK 5,313 thousand and 52%, respectively, which is in line with the company’s gross profit and margin for the full year. This is slightly lower than the previous year which is related to, through the acquisition of Commonsense Israel, inherited license business.
Profit – The group’s result after net financial items for the fourth quarter amounted to SEK -8,122 (-43,858) thousand. For the full year, the corresponding result is SEK -36,857 (-73,688) thousand.
Financial position and liquidity – Cash and bank as of December 31, 2022, amounted to SEK 3,566 (10,153) thousand.
With the rights issue of units carried out in January 2023, approx. SEK 55 million will be added to the company before issue costs. Net balance after payment of long-term liabilities and after issue costs amounts to approx. SEK 22 million, which strengthens the group’s financial position and enables the company to continue developing the product portfolio and switch up production and sales within all of the group’s business areas.
Shareholders equity – The group’s equity as of 31 December 2022 amounted to SEK 47,091 (52,017) thousand, which gives an equity ratio of 55 (62) percent.
Liabilities – The group’s liabilities amounted, as of 31 December 2022, to SEK 38,660 (31,483) thousand. Of which short-term amounts to SEK 35,066 thousand. Of these, SEK 19,331 thousand have been repaid in connection with the rights issue.
Organization – During the period, the average number of employees was 34 (34). At the end of the period, the number of employees amounted to 34 (34).
| INCOME STATEMENT | |||||
| Peptonic Group | |||||
| 3 mon | 3 mon | 12 mon | 12 mon | ||
| oct-dec | oct-dec | jan-dec | jan-dec | ||
| KSEK | Note | 2022 | 2021 | 2022 | 2021 |
| Operating income | |||||
| Sales of products | 10 191 | 5 642 | 43 634 | 31 643 | |
| Other operating income | 1 733 | 610 | 2 770 | 622 | |
| Total operating income | 11 924 | 6 252 | 46 404 | 32 265 | |
| Operating expenses | |||||
| Cost of goods | -5 890 | -2 254 | -20 239 | -12 573 | |
| Other external expenses | 1 | -7 405 | -14 876 | -34 186 | -45 690 |
| Personnel costs | -4 585 | -8 905 | -21 922 | -19 430 | |
| Depreciation | -885 | -24 409 | -3 491 | -27 055 | |
| Other operating costs | -49 | 218 | -172 | -1 234 | |
| Total operating expensses | -18 814 | -50 226 | -80 010 | -105 983 | |
| Operating loss | -6 890 | -43 974 | -33 606 | -73 718 | |
| Net financial income/expense | -1 232 | 116 | -3 251 | 30 | |
| Loss before taxes | -8 122 | -43 858 | -36 857 | -73 688 | |
| Taxes | 0 | 0 | 0 | 0 | |
| Net loss for the period | -8 122 | -43 858 | -36 857 | -73 688 |
| BALANCE SHEET | |||
| Peptonic Group | |||
| 31-dec | 31-dec | ||
| KSEK | Note | 2022 | 2021 |
| Assets | |||
| Non-Current assets | |||
| Intangeble assets | 2 | 50 098 | 52 210 |
| Tangeble assets | 3 | 4 299 | 4 204 |
| Financial assets | 0 | 0 | |
| Total non-current assets | 54 398 | 56 414 | |
| Current assets | |||
| Stock | 15 368 | 10 323 | |
| On going fund raising | 0 | 0 | |
| Other receivbles | 8 267 | 5 166 | |
| Tax receivable | 89 | 524 | |
| Prepaid expenses and accrued income | 4 064 | 920 | |
| Liquid assets | 3 566 | 10 153 | |
| Total current assets | 31 354 | 27 086 | |
| Total assets | 85 752 | 83 500 |
| CHANGES IN EQUITY | |||||||
| Peptonic Group | |||||||
| KSEK | Share Capital | Develop-ment cost fund | Ongoing right issue | Share Premium reserve non-restricted | Accumul-ated losses | Total shareholders equity | |
| Opening balance January 1, 2020 | 16 291 | 11 186 | 2 327 | 240 399 | -152 383 | 117 820 | |
| Net loss for the year | -73 688 | -73 688 | |||||
| Transfering fund | -1 569 | 1 569 | 0 | ||||
| Right issue | 2 873 | -2 327 | 6 954 | 7 500 | |||
| On going right issues | 400 | 400 | |||||
| Issue expenses | -15 | -15 | |||||
| Closing balance December 31, 2020 | 19 164 | 9 617 | 0 | 247 338 | -224 102 | 52 017 | |
| Opening balance January 1, 2021 | 19 164 | 9 617 | 0 | 247 338 | -224 102 | 52 017 | |
| Net loss for the year | -36 857 | -36 857 | |||||
| Transfering fund | -2 225 | 2 225 | 0 | ||||
| Right issue | 5 110 | 26 667 | 33 728 | ||||
| On going right issues | 0 | 0 | |||||
| Coneversion difference | 547 | 547 | |||||
| Issue expenses | -3 444 | ||||||
| Closing balance December 31, 2021 | 24 274 | 7 392 | 0 | 274 005 | -258 187 | 45 992 |
| STATMENT OF CASH FLOW | |||
| Peptonic Group | |||
| 12 mon | 12 mon | ||
| jan-dec | jan-dec | ||
| KSEK | 2022 | 2021 | |
| CASH FLOW FROM OPERATIONS BEFORE CHANGES IN WORKING CAPITAL | |||
| Operating profit/loss | -36 857 | -73 688 | |
| Non-cash flow items | 3 491 | 26 840 | |
| Paid tax | 0 | 0 | |
| NET CASH FLOW FROM OPERATING ACTIVITIES BEFORE CHANGES IN WORKING CAPITAL | -33 366 | -46 848 | |
| Increase (-) decrease (+) inventory | -5 045 | -4 190 | |
| Increase (-) decrease (+) receivables | -5 810 | 3 333 | |
| Increase (-) decrease (+) liabilities | -357 | 7 365 | |
| NET CASH FLOW FROM OPERATING ACTIVITIES | -44 579 | -40 340 | |
| CASH FLOW FROM INVESTING ACTIVITIES | |||
| Investment in immaterial assets, net | -987 | -1 256 | |
| Investment in material assest, incl subsidaries | 0 | -3 024 | |
| Investment in financial assets, net | 0 | 0 | |
| Divestment / reduction of financial assets | 1 184 | 0 | |
| NET CASH FLOW FROM INVESTING ACTIVITIES | 197 | -4 280 | |
| CASH FLOW FROM FINANCING ACTIVITIES | |||
| Rights issue | 33 704 | 7 500 | |
| Issue expenses | -3 444 | -15 | |
| Bridgeloan | 7 534 | 7 500 | |
| NET CASH FLOW FROM FINANCING ACTIVITIES | 37 794 | 14 985 | |
| TOTAL CASH FLOW FOR THE YEAR | -6 587 | -29 159 | |
| Cash and cash equivalents at beginning of period | 10 153 | 39 312 | |
| CASH AND CASH EQUIVALENTS AT END OF THE PERIOD | 3 566 | 10 153 |
Audit
This year-end report has not been subject to be reviewed by the company’s auditors.
Proposal for allocation of profit
The board proposes that no dividends are paid for the financial year 2022.
Assurance
The board and the managing director assure that the year-end report provides a fair overview of the company’s operations, position and results.
FINANSIELL KALENDER
Year-end report, 2022 2023-02-24
Annual General Meeting 2023-04-20
Quarterly report, 1 2023-04-24
Quarterly report, 2 2023-08-11
Quarterly report, 3 2023-10-24
Year-end report, 2023 2024-02-23
The annual general meeting will be held on April 20, 2023, in Stockholm. The annual report will be available on the Company’s website, www.peptonicmedical.se, no later than 3 weeks before the general meeting and can then also be requested from the Company by e-mail erik.sundquist@peptonicmedical.se.
Stockholm on 24th February, 2023
Jan Bardell, Chairmen of the Board Daniel Rudeklint, Board member
Anders Blom, Board member Anders Norling, Board member
Erik Sundquist, CEO
For more information please contact:
Erik Sundquist, CEO PEPTONIC Medical AB. Phone: +46 722 499 043
